TROP2 and immune gene expression by African ancestry in triple-negative breast cancer
- 1Howard University
Abstract
Purpose: TROP2 is a treatment target in triple-negative breast cancer (TNBC). TACSTD2 encodes TROP2, while PDCD1 encodes the immune protein PD-1. We investigated whether these genes differ by race or African genetic ancestry and whether the reported link between higher TACSTD2 and lower immune-gene expression partly reflects the mixture of cells in tumor samples. Methods: We analyzed TNBC tumors from TCGA (n = 107) and GSE268851 (n = 253; ancestry data for 229), together with spatial, normal-breast, and protein datasets. Regression models adjusted for age, tumor stage, and a score based on epithelial gene expression. We compared TACSTD2 with other epithelial markers using paired bootstrap analysis. Results: TACSTD2 was detected in nearly all tumors, with no significant differences by race or ancestry. Higher African ancestry was linked to higher PDCD1 expression in TCGA (P = 0.00039), but not in GSE268851. In GSE268851, higher TACSTD2 remained associated with lower CD8A, GZMB, and cytotoxic score after epithelial adjustment (all q < 0.003). These associations were stronger than those for EPCAM; the CD8A association was also stronger than that for KRT8. TACSTD2 was 1.55-fold higher in TNBC than in normal breast and correlated with TROP2 protein (Spearman rho = 0.74). Conclusion: TACSTD2 was widely expressed in the TNBC groups studied, while the ancestry-PDCD1 association differed between cohorts. Epithelial gene expression did not fully explain some negative TACSTD2-immune associations, and some were stronger than those for other epithelial markers such as EPCAM.
Related
- Integrative Omics Analysis Reveals Functional Variants of Hemoglobin Zeta (HBZ) as an Ancestry-Specific Risk Factor for Triple-Negative Breast Cancer
- The Prognostic Role of Vimentin Expression in Triple‐Negative Breast Cancer: A Retrospective Cohort Study
- Prognostic Significance of p53 Immunohistochemical Expression and Molecular Characterization of TP53 Variants in Triple-Negative Breast Cancer After Neoadjuvant Chemotherapy
- Prediction of ROR1 and CAV1 expression from whole-exome sequencing of tumor tissue and plasma cfDNA to infer the efficacy of B013 plus nab-paclitaxel in triple-negative breast cancer
- Safety of concurrent immune checkpoint inhibitor therapy during postoperative radiotherapy for triple-negative breast cancer: A preliminary retrospective analysis
BibTeX
@misc{okechukwu2026trop2,
title = {{TROP2 and immune gene expression by African ancestry in triple-negative breast cancer}},
author = {A. C. Okechukwu and E. O. Akala},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.762976},
url = {https://www.biorxiv.org/content/10.64898/2026.10.29.762976v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - TROP2 and immune gene expression by African ancestry in triple-negative breast cancer
AU - A. C. Okechukwu
AU - E. O. Akala
PY - 2026
DA - 2026/10/29
PB - bioRxiv
DO - 10.64898/2026.10.29.762976
UR - https://www.biorxiv.org/content/10.64898/2026.10.29.762976v1
AB - Purpose: TROP2 is a treatment target in triple-negative breast cancer (TNBC). TACSTD2 encodes TROP2, while PDCD1 encodes the immune protein PD-1. We investigated whether these genes differ by race or African genetic ancestry and whether the reported link between higher TACSTD2 and lower immune-gene expression partly reflects the mixture of cells in tumor samples. Methods: We analyzed TNBC tumors from TCGA (n = 107) and GSE268851 (n = 253; ancestry data for 229), together with spatial, normal-breast, and protein datasets. Regression models adjusted for age, tumor stage, and a score based on epithelial gene expression. We compared TACSTD2 with other epithelial markers using paired bootstrap analysis. Results: TACSTD2 was detected in nearly all tumors, with no significant differences by race or ancestry. Higher African ancestry was linked to higher PDCD1 expression in TCGA (P = 0.00039), but not in GSE268851. In GSE268851, higher TACSTD2 remained associated with lower CD8A, GZMB, and cytotoxic score after epithelial adjustment (all q < 0.003). These associations were stronger than those for EPCAM; the CD8A association was also stronger than that for KRT8. TACSTD2 was 1.55-fold higher in TNBC than in normal breast and correlated with TROP2 protein (Spearman rho = 0.74). Conclusion: TACSTD2 was widely expressed in the TNBC groups studied, while the ancestry-PDCD1 association differed between cohorts. Epithelial gene expression did not fully explain some negative TACSTD2-immune associations, and some were stronger than those for other epithelial markers such as EPCAM.
ER -